Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Intracellular immunity

A technology of immunoglobulins and compounds, applied in the direction of immunoglobulins, antiviral immunoglobulins, antibacterial drugs, etc., can solve problems such as unclear mechanism of action

Inactive Publication Date: 2013-06-26
MEDICAL RESEARCH COUNCIL
View PDF23 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the mechanism of action is unclear as the doses used are thought to be lower than those at which antiviral effects are observed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Intracellular immunity
  • Intracellular immunity
  • Intracellular immunity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0184] Example 1: Antibodies are internalized

[0185] Antibodies are thought to not normally enter the cytosol during viral infection. To test this claim, we pre-incubated adenovirus (a human virus model that causes respiratory disease) with antibodies and added viral particles to cultured HeLa cells. Adenovirus was chosen because it is a non-enveloped virus whose capsid is naturally exposed to serum antibodies prior to cell infection. Thirty minutes after infection, cells were fixed, and a fluorescent anti-IgG antibody was added to detect antibody-coated viral particles. as in figure 1 As seen in A, antibody-coated virus particles successfully infect cells. Similar results were obtained using polyclonal anti-hexon antibodies and human serum IgG. Adenoviruses enter cells by binding to CAR receptors and are endocytosed. We found that the addition of antibodies did not prevent this process, and the antibodies remained attached to the virus after entry.

Embodiment 2

[0186] Example 2: TRIM21-mediated neutralization of intracellular virus

[0187] To understand whether cytosolic TRIM21 is accessible to antibody-coated viruses, we co-stained for TRIM21. Such as figure 1 In A, TRIM21 is efficiently recruited to antibody-coated virus particles.

[0188] We then examined the role of TRIM21 recruitment to viral particles by quantifying the level of adenovirus infection. We used viruses carrying the GFP gene so that the efficiency of infection could be determined by flow cytometry analysis. Standard virus neutralization assays were performed on HeLa cells pretreated with control siRNA, TRIM21 siRNA, interferon-α (IFNα), or IFNα and TRIM21 siRNA ( figure 1 B). To account for the cytotoxicity and variable cell death between these different conditions, we measured the reduction in infection due to the addition of antibodies. In the absence of antibodies, adenovirus infects -50% of cells. The percentage of infected cells decreased rapidly with ...

Embodiment 3

[0190] Example 3: Variation of Conditions

[0191] To confirm that TRIM21 / antibody intracellular neutralization is not adenovirus specific, we examined its effect on Coxsackievirus B3 infection. Coxsackievirus B3 is a picornavirus of the same genus as poliovirus and is the leading cause of aseptic meningitis. HeLa cells pretreated with the combination of TRIM21 siRNA and IFNαA as described above were infected with a replication competent strain carrying the GFP receptor gene. Infection time is limited to figure 1 D). Removal of TRIM21 in IFNα-treated cells restored the level of infection to that of untreated cells, demonstrating a TRIM21-dependent effect.

[0192] We confirmed the robustness of this phenotype by examining the effect of different siRNA sequences, cell types and antibody types. Such as figure 2 As seen in A, different TRIM21 siRNAs with different target sequences reversed antibody neutralization of adenovirus infection by knockdown of TRIM21 levels. Second...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A compound comprising a ligand which binds, directly or indirectly, specifically to an antigen of a pathogen, provided that said ligand is not the PRYSPRY domain of TRIM21; and a RING domain and / or an inducer of TRIM21 expression.

Description

technical field [0001] The present invention relates to compounds which are conjugates of pathogen-specific ligands and RING domains. In one embodiment, the RING domain is derived from a TRIM polypeptide, eg TRIM21. Background technique [0002] Viruses and their hosts have co-evolved over millions of years, which has led to the traditional division of the immune complex system into innate and adaptive responses 1 . Innate immunity includes germline-encoded receptor and effector mechanisms that recognize pathogen-associated molecular patterns, or PAMPs 2 . The advantage of innate immunity is that it is rapid and pervasive; however, viruses are adept at evading recognition by suppressing innate immunity or by altering their molecular patterns. In contrast, adaptive immunity is able to "cure" an infected host and provide protection from future infection. Unlike the PAMP receptors of innate immunity, adaptive immunity uses proteins such as antibodies to target pathogens. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/08C07K14/435
CPCA61K2039/505C07K16/08C07K2317/77C07K2319/00C12N15/1137C12N2310/14A61P31/04A61P31/12C07K14/47C07K16/00
Inventor L·C·詹姆士D·L·马勒里W·A·迈克伊万S·R·彼得古德
Owner MEDICAL RESEARCH COUNCIL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com